Literature DB >> 20094785

Role of Helicobacter pylori infection in gastroduodenal damage in patients starting NSAID therapy: 4 Months follow-up study.

Aleksandra Sokic-Milutinovic1, Miodrag Krstic, Brigita Rozer-Smolovic, Tamara Alempijevic.   

Abstract

AIMS: We aimed to determine differences in gastroduodenal damage related to the presence of Helicobacter pylori (Hp) in patients starting long-term NSAID therapy. Seventy-one candidates for chronic NSAIDs therapy (33 Hp negative and 38 Hp positive) entered the study and underwent upper GI endoscopy before, and 8 and 16 weeks after, continuous NSAID therapy.
RESULTS: Lanza score increased in both Hp positive and negative patients in the course of NSAID therapy (P < 0.001), being significantly higher in Hp positive than Hp negative (4.31 ± 1.33 vs 3.15 ± 1.95, P < 0.05) after 16 weeks of follow-up. In gastric mucosa, no significant difference in mean Lanza score was observed between the two groups. Duodenal ulcer was diagnosed in 18 (36.8%) Hp positive and 1 (3%) Hp negative patient (P < 0.05).
CONCLUSIONS: Hp is more closely related to duodenal than gastric mucosal injury in NSAID users. Risk for duodenal ulcer in Hp-infected individual increases after 4 months of NSAID therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20094785     DOI: 10.1007/s10620-009-1097-5

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  28 in total

1.  Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial.

Authors:  Francis K L Chan; K F To; Justin C Y Wu; M Y Yung; W K Leung; Timothy Kwok; Y Hui; Henry L Y Chan; Cynthia S Y Chan; Elsie Hui; Jean Woo; Joseph J Y Sung
Journal:  Lancet       Date:  2002-01-05       Impact factor: 79.321

2.  Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis.

Authors:  Jia Qing Huang; Subbaramiah Sridhar; Richard H Hunt
Journal:  Lancet       Date:  2002-01-05       Impact factor: 79.321

Review 3.  Current European concepts in the management of Helicobacter pylori infection--the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG).

Authors:  P Malfertheiner; F Mégraud; C O'Morain; D Bell; G Bianchi Porro; M Deltenre; D Forman; G Gasbarrini; B Jaup; J J Misiewicz; J Pajares; M Quina; E Rauws
Journal:  Eur J Gastroenterol Hepatol       Date:  1997-01       Impact factor: 2.566

4.  Three-year prospective validation of a pre-endoscopic risk stratification in patients with acute upper-gastrointestinal haemorrhage.

Authors:  Ewen A Cameron; J Nick Pratap; Tracey J Sims; Simone Inman; Donna Boyd; Maureen Ward; Stephen J Middleton
Journal:  Eur J Gastroenterol Hepatol       Date:  2002-05       Impact factor: 2.566

5.  Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: a case-control study.

Authors:  C Aalykke; J M Lauritsen; J Hallas; S Reinholdt; K Krogfelt; K Lauritsen
Journal:  Gastroenterology       Date:  1999-06       Impact factor: 22.682

Review 6.  Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives.

Authors:  F Halter; A S Tarnawski; A Schmassmann; B M Peskar
Journal:  Gut       Date:  2001-09       Impact factor: 23.059

Review 7.  Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users.

Authors:  M Vergara; M Catalán; J P Gisbert; X Calvet
Journal:  Aliment Pharmacol Ther       Date:  2005-06-15       Impact factor: 8.171

8.  Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial.

Authors:  K C Lai; C S Lau; W Y Ip; B C Y Wong; W M Hui; W H C Hu; R W M Wong; S K Lam
Journal:  Aliment Pharmacol Ther       Date:  2003-03-15       Impact factor: 8.171

9.  Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial.

Authors:  J Labenz; A L Blum; W W Bolten; B Dragosics; W Rösch; M Stolte; H R Koelz
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

Review 10.  Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment.

Authors:  F K L Chan; D Y Graham
Journal:  Aliment Pharmacol Ther       Date:  2004-05-15       Impact factor: 8.171

View more
  1 in total

Review 1.  Hematologic manifestations of Helicobacter pylori infection.

Authors:  Germán Campuzano-Maya
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.